MONTREAL, July 5 /CNW Telbec/ - Theratechnologies (TSX: TH) announced today that on June 30 a patient in Atlanta, Georgia, became the first to begin treatment in the Phase III clinical trial testing Theratechnologies' TH9507 (ThGRF) compound in HIV associated lipodystrophy, a condition that affects many patients undergoing HIV antiretroviral therapy. "I am pleased to report that the Phase III study got off the ground on June 30, in keeping with our mid-year objective," noted Yves Rosconi, President and Chief Executive Officer of Theratechnologies. "Including the Atlanta site, we now have 6 of the projected 35 sites actively recruiting patients and we are working hard towards opening the remaining 29 sites and recruiting the 400 patients we need to complete the study. Our goal is to announce results in the second half of 2006," Mr. Rosconi added. HIV-associated lipodystrophy is characterized by changes in distribution of adipose tissue (fat-containing tissue), dyslipidemia and glucose intolerance. The changes in fat distribution include visceral adipose tissue (VAT) accumulation and/or the loss of subcutaneous fat, generally in the limbs and facial area. The multi-center, randomized, double-blind, placebo- controlled Phase III clinical trial is investigating the safety and efficacy of TH9507 in reducing excess VAT in approximately 400 patients by administering 2 mg daily for a period of 26 weeks. There will also be an extension phase of the study lasting an additional 26 weeks to assess long-term safety and the effects of discontinuing treatment. A Canadian component of the study is being prepared and will be led by Dr. Julian Falutz, Director of the HIV Metabolic Clinic at the Montreal General Hospital and Assistant Professor at the McGill University Medical School. Dr. Falutz has been treating HIV patients since the beginning of the epidemic in the early 1980s. "With combination antiretroviral therapies now available, the prognosis and quality of life for treated HIV patients have improved dramatically," Dr. Falutz stated. "However, toxicity may be significant and treatment-limiting at times. One of the most important side effects is HIV-associated lipodystrophy, with its potential to cause important body-shape changes as well as lipid and glucose abnormalities," he added. Dr. Steven Grinspoon, Director, Program in Nutritional Metabolism at Massachusetts General Hospital, and Associate Professor of Medicine at Harvard University is the Lead Investigator for the clinical study in the United States. Dr. Grinspoon stresses the importance of finding an effective treatment for HIV-associated lipodystrophy patients. "This condition increases their risk of developing cardiovascular disease and type 2 diabetes, and what's also worrisome, the body abnormalities related to lipodystrophy can stigmatize patients and discourage compliance with their HIV regimens," Dr. Grinspoon explained. Dr. Melanie Thompson, principal investigator of the AIDS Research Consortium of Atlanta, enrolled the first patient on the study and was an investigator on the Phase II clinical trial of TH9507. Dr Thompson is former Chair of the U.S. Office of AIDS Research Therapeutics Research Working group and serves on the International AIDS Society-USA Antiretroviral Treatment Guidelines Panel. "We are truly excited to be initiating this study because of the need for treatment for lipodystrophy. This disorder is a source of severe stress for patients and also may be associated with diabetes, high cholesterol and other factors for cardiovascular disease," Dr. Thompson said. "There has been a lot of interest in this particular drug candidate because Phase II clinical trial results indicate that TH9507 may reduce VAT effectively and safely, even in patients with impaired glucose tolerance," she added. Mr. Rosconi believes that a specialized indication like HIV-associated lipodystrophy is an ideal entry point to bring TH9507 to the market. "Our market studies indicate that among the 1.1 million HIV-positive patients in North America and Europe, nearly 200,000 suffer from HIV-associated lipodystrophy with excess VAT accumulation", Mr. Rosconi said. "It's a potential market of several hundred million dollars, and yet, the scale of the Phase III clinical trials and the relatively small number of doctors we will need to speak to about prescribing TH9507 make this a manageable project for a company our size," he concluded. About TH9507 TH9507 is a stabilized analogue of the growth hormone-releasing factor (GRF) that induces the production and secretion of growth hormone in a specific, physiological, controlled and pulsatile fashion. This property makes it a strong candidate as a potential treatment for many diseases characterized by a reduction in growth hormone secretion. About Theratechnologies Theratechnologies (TSX: TH) is a Canadian biopharmaceutical company engaged in the discovery and development of therapeutic peptides in the field of endocrinology and metabolism. The Company uses proprietary discovery technologies to expand its product portfolio. The most advanced clinical program (Phase III) targets HIV-associated lipodystrophy with its lead compound, TH9507 (ThGRF). The Company is investigating other potential indications for TH9507 and it also has an interesting product pipeline targeting type 2 diabetes. This press release contains forward-looking statements regarding the clinical development of TH9507 and its future commercialization in the indication described above. Such statements inherently involve numerous risks and uncertainties, including the availability of funds and resources, the success and timely completion of clinical trials and the granting of the necessary authorizations. Actual future results may differ materially from the anticipated results. Investors are cautioned against placing undue importance on forward-looking information contained herein and should consult the Company's 2004 Annual Report, which contains a more exhaustive analysis of risks and uncertainties connected to the businesses of the Company.
Theratechnologies launches Phase III clinical trial for TH9507 (ThGRF) treating HIV-associated lipodystrophy
Story so far
Earlier from Theratechnologies
- Theratechnologies closes the sale of its investment in Celmed BioSciences
- Theratechnologies: four scientific posters at the Endocrine Society Annual Meeting
- Theratechnologies reports on a positive meeting with Health Canada for its ThGRF Phase III program
- PRESS CONFERENCE - Theratechnologies Inc. - Invitation to Media
- Theratechnologies: Financial results for the first quarter of 2005 and recent operating highlights
Later from Theratechnologies
- Theratechnologies: Financial results for the second quarter and recent operating highlights
- European pharmaceutical executive joins the Board of Theratechnologies
- Theratechnologies: TH9507 Phase 3 study advancing rapidly
- Theratechnologies' common shares now eligible for inclusion in the SMB Growth Stock Plan
- Market Regulation Services - Trading Halt - Theratechnologies Inc. - TH
Follow Theratechnologies into a list and get an email when it puts out news.
Follow Theratechnologies